dc.contributor
Institut Català de la Salut
dc.contributor
[Corres-Mendizabal J] Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain. [Zacchi F] Section of Innovation BiomedicineOncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Martín-Martín N] Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Translational Prostate Cancer Research Laboratory, CIC bioGUNE-Basurto, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Carracedo A] Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Translational Prostate Cancer Research Laboratory, CIC bioGUNE-Basurto, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain. Ikerbasque, Basque Foundation for Science, Bilbao, Spain. Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), Bilbao, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Corres-Mendizabal, Jon
dc.contributor.author
Martín-Martín, Natalia
dc.contributor.author
Carracedo, Arkaitz
dc.contributor.author
Zacchi, Francesca
dc.contributor.author
Mateo, Joaquin
dc.date.accessioned
2025-10-25T05:39:08Z
dc.date.available
2025-10-25T05:39:08Z
dc.date.issued
2024-09-25T10:02:54Z
dc.date.issued
2024-09-25T10:02:54Z
dc.identifier
Corres-Mendizabal J, Zacchi F, Martín-Martín N, Mateo J, Carracedo A. Metastatic hormone-naïve prostate cancer: a distinct biological entity. Trends in Cancer. 2024 Sep;10(9):825–41.
dc.identifier
https://hdl.handle.net/11351/11963
dc.identifier
10.1016/j.trecan.2024.06.005
dc.identifier.uri
http://hdl.handle.net/11351/11963
dc.description.abstract
Models experimentals; Metàstasi; Càncer de pròstata
dc.description.abstract
Modelos experimentales; Metástasis; Cáncer de próstata
dc.description.abstract
Experimental models; Metastasis; Prostate cancer
dc.description.abstract
Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic prostate cancer and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis and response to therapy. A more precise treatment of mHNPC, guided by evidence-based biomarkers, remains an unmet medical need. In addition, the limited number of representative laboratory models of mHNPC hampers the translation of basic research into clinical applications. We provide a comprehensive overview of the clinical and biological features that characterize mHNPC, highlight molecular data that could explain the unique prognostic characteristics of mHNPC, and identify key open questions.
dc.description.abstract
We are thankful to Kathrin Keim for support with English editing. The work of A.C. is supported by the Basque Department of Industry, Tourism, and Trade (Elkartek), the BBVA Foundation (Becas Leonardo), the Ministerio de Ciencia e Innovación (MICINN; PID2022-141553OB-I0 ERDF (European Regional Development Fund)/EU]; the Fundación CRIS Contra el Cáncer ( PR_EX_2021-22 ), Severo Ochoa Excellence Accreditation ( CEX2021-001136-S ), the European Training Networks Project ( H2020-MSCA-ITN-308 2016 721532), the Spanish Association Against Cancer (AECC; GCTRA18006CARR ), the Fundación Jesús Serra, the iDIFFER Network of Excellence ( RED2022-134792-T ), the AstraZeneca Award for young scientists ( 2023 call) and the European Research Council (consolidator grant 819242 ). CIBERONC was cofunded with FEDER funds and funded by the Instituto de Salud Carlos III (ISCIII). J.M. is supported by a CRIS Talent Award ( TALENT20-10 ) and a Department of Defense Congressionally Directed Medical Research Program (CDMPR) Physician-Science Award ( PC220307 ). VHIO authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for financial support as a Center of Excellence Severo Ochoa ( CEX2020-001024-S/AEI/10.13039/501100011033 ), the Cellex Foundation for providing research facilities and equipment, and the Foundation for Oncological Studies and Research (FERO) and the Centres de Recerca de Catalunya (CERCA) Programme from Generalitat de Catalunya for their support.
dc.format
application/pdf
dc.relation
Trends in Cancer;10(9)
dc.relation
https://doi.org/10.1016/j.trecan.2024.06.005
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Pròstata - Càncer - Tractament
dc.subject
Pròstata - Càncer - Prognosi
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms
dc.subject
Other subheadings::Other subheadings::/therapy
dc.subject
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata
dc.subject
Otros calificadores::Otros calificadores::/terapia
dc.subject
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
dc.title
Metastatic hormone-naïve prostate cancer: a distinct biological entity
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
